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Purpose: Vogt-Koyanagi-Harada (VKH) disease is an immune-mediated disorder with autoimmune insult directed
against antigens associated with melanocytes. The genetic predisposition among VKH has not been explored in Saudi
Arabia. So, the purpose of this study was to investigate the association of human leukocyte antigen (HLA)-DRB1 alleles
to VKH patients and to clarify the molecular genetic mechanism underlying the susceptibility or resistance to VKH disease.
Methods: Genomic DNA from a total of 30 patients with VKH and 29 control subjects was extracted from peripheral
blood, and HLA-DRB1 alleles were typed by polymerase chain reaction and sequence based typing (SBT).
Results: We found a statistically significant difference in the prevalence of HLA-DRB1 *0405 between the VKH patients
and control subjects (p<0.05). Eleven out of thirty (36.6%) patients with VKH had positive HLA-DRB1 *0405 compared
to two out of twenty-nine (6.9%) control subjects. However, there were no statistically significant differences in the HLA-
DRB1 alleles *01, *0101, *0102, *0301, *04, *0403, *0404, *0701, *1001, *1101, *1112, *1301, *1302, *1303, *1501,
and *1502 between the VKH patients and controls.
Conclusions: Patients with VKH had significantly greater incidence of HLA-DRB1 *0405 when compared to age  and
sex-matched  controls.  Consequently,  this  finding  suggests  that  HLA-DRB1  *0405  allele  might  play  a  role  in  the
pathogenesis of VKH disease.
Vogt-Koyanagi-Harada (VKH) disease is a multisystem
autoimmune disorder mediated by Th1 lymphocytes reacting
against  antigens  associated  with  the  melanocytes  such  as
tyrosinase and related proteins [1-5]. The disease afflicts the
uvea in the eye leading to chronic inflammation and may lead
to loss of vision [6]. The disease occurs in stages with early
involvement of the meninges followed by auditory, ocular,
and integumentary structures. During the early manifestation
of the disease, patients may develop malaise, fever, headache,
nausea, neck stiffness, and tinnitus. Following an acute onset,
the disease becomes chronic and progressive with bilateral
choroiditis  and  panuveitis  associated  with  nummular
chorioretinal lesions or exudative retinal detachment. Patients
may present with bilateral diffuse granulomatous uveitis. No
cutaneous manifestations are noted during the acute phase of
the  disease,  but  alopecia,  vitiligo,  and  poliosis  may
subsequently appear weeks or months after the acute onset of
the disease. Tinnitus and dysacusia may occur during the
initial  phases  of  the  disorder.  Thus  far,  there  are  no
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serodiagnostic tests for this disease. and the diagnosis remains
clinical.  The  disease  presents  with  bilateral  ocular
involvement  alone  (probable)  VKH  or  bilateral  ocular
involvement  and  central  nervous  system  (CNS)  and
integumentary involvement (complete) VKH or with either
CNS or integumentary involvement (incomplete) VKH [7].
In VKH patients, there is no history of penetrating ocular
trauma and no clinical or laboratory evidence suggestive of
other ocular disorders. In the complete form during acute
onset, there is evidence of choroiditis with a focal area of
subretinal fluid or bullous exudative retinal detachment. There
is diffuse choroidal thickening and multifocal chorioretinal
infiltrates. In the late manifestation of the disease, patients
may  develop  sunset  glow  fundus,  alopecia,  poliosis,  and
vitiligo.  In  the  incomplete  form  of  VKH,  patients  show
evidence of bilateral ocular involvement. There is an acute
phase of malaise, fever, headache, nausea, and neck stiffness
or alopecia, poliosis, or vitiligo. In the probable form of VKH,
it  is  bilateral  ocular  involvement  with  no  association  of
integumentary findings or neurologic findings. VKH appears
to occur commonly among communities with dark pigment
such as Native Americans, Middle Easterners, Asians, and
Indians but not in blacks of sub-Saharan African descent. The
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1876disease is uncommon among Caucasians [7]. Increased risk
among those with certain HLA genotypes showing strong
association  with  human  leukocyte  antigen  (HLA)-DRB1
*0405 and HLA-DRB1 *0401 have been reported in several
populations [8-12]. In Saudi Arabia, VKH is a common cause
of uveitis, yet there has been no previous study on the genetic
predisposition among patients with VKH disease [6]. Thus,
we intended to explore and analyze the frequency and the
association of HLA-DRB1 alleles among patients with VKH
in Saudi Arabia and to investigate its potential role in the
disease manifestation.
METHODS
Study population: Thirty patients (12 male and 18 female)
with confirmed VKH as defined by the revised diagnostic
criteria  in  the  report  of  the  International  Committee  on
Nomenclature [7] were recruited for this study. Patients were
divided into two groups, (1) complete VKH disease and (2)
incomplete VKH disease, to find out whether there is any
genetic  difference  in  patients  with  different  clinical
manifestations  [7].  Patients  with  probable  VKH  were  not
included.  Twenty-nine  age-  and  sex-matched  healthy
volunteers  who  attended  the  Blood  Bank  at  King  Faisal
Specialist Hospital and Research Centre (KFSHRC) (Riyadh,
Saudi Arabia) were included as the control. This study was
approved by the King Faisal Specialist Hospital and Research
Centre Institutional Review Board and maintained the strict
adherence  to  the  Declaration  of  Helsinki  for  research
involving  human  subjects.  Written  informed  consent  was
obtained from all the participants before study enrollment.
Diagnostic criteria: Patients with complete or incomplete
VKH  were  investigated  in  this  study.  The  diagnosis  of
complete VKH disease was made as previously described
[7]. The diagnosis of complete VKH when the following five
criteria: (1) no history of penetrating injury or surgery; (2) no
clinical  or  laboratory  evidence  suggestive  of  other  ocular
diseases;  (3)  bilateral  ocular  involvement  consisting  of
anterior uveitis and diffuse or multifocal choroiditis with or
without evidence of a retinal detachment. Late manifestations
or  ocular  findings  consist  of  areas  of  retinochoroidal
depigmentations, nummular chorioretinal depigmented scar,
retinal  epithelial  clumping,  and  peripapillary  chorioretinal
atrophy  with  or  without  chronic  anterior  uveitis,  (4)
neurologic/auditory findings include meningismus, malaise,
fever, headache, stiffness of the back or neck, tinnitus or
cerebrospinal fluid (CSF) pleocytosis, and (5) integumentary
findings of alopecia, poliosis, and vitiligo.
The diagnosis of incomplete VKH were made by the
following criteria: (1) no history of penetrating ocular injury,
(2) no clinical or laboratory evidence suggestive of other
ocular  disease,  (3)  bilateral  ocular  involvement,  and  (4)
neurologic auditory findings and/or cutaneous findings such
as vitiligo and poliosis [7].
Extraction of genomic DNA: Genomic DNA was isolated
from the peripheral blood using the Puregene TM extraction Kit
(Gentra Inc., Foster City, CA) following the manufacturer’s
recommendation. The extracted DNA was stored at –80 °C
for long-term usage. The DNA purity and concentration was
determined using a NanoDrop spectrophotometer (Thermo
Scientific, Wilmington, DE).
Determination of HLA-DRB1 allele: The determination of the
HLA-DRB1 alleles was performed by using the Allele SEQR
HLA Sequencing kit with Heterozygous ambiguity resolving
primers (AlleleSEQR HLA Sequencing kit+ HARPs; Atria
Genetics, Inc. South San Francisco, CA). The principle of this
test relies on two key technologies that are described below.
PCR  amplification  of  the  HLA-DRB1  gene—The
genes of interest were amplified using 8 µl of gene-specific
polymerase chain reaction (PCR) pre-mixes (gene specific
oligonucleotide  primer  mixes  in  a  Tris-based  PCR  buffer
containing dNTPs and MgCl2) and 0.1 µl AmpliTaq Gold
(Applied Biosystems Inc. Foster City, CA). A total of 40 ng
of genomic DNA was added, and the volume was finally
adjusted to 10 µl with sterile water. Amplification of the gene
was done on PCR thermal cycler (MJ Research,GMI, Ramsay,
Minnesota). PCR was initiated with an initial denaturation at
95 °C for 10 min followed by amplification of 36 cycles at
96 °C for 20 s, 60 °C for 30 s , and finally 72 °C for 3 min.
This was followed by cleaning of the amplified product using
ExoSAP-IT  (Exonuclease  I  and  Shrimp  Alkaline
Phosphatase, together in a specially formulated buffer) from
Usb Corporation (Cleveland, OH) and was stored for future
use.
Sequencing  of  HLA-DRB1  alleles—The  amplified
product serves as a DNA sequencing template in the reaction.
Eight microliters of sequencing mix was dispensed in separate
reaction tubes with 2 µl of the ExoSAP-treated PCR product.
The thermal condition for the sequencing reaction was as
follows: 25 cycles for 20 s at 96 °C, 30 s at 50 °C, and 2 min
at 60 °C. Finally, the sequence reaction was purified using
DyeEx  2.0  spin  kit  (Qiagen  Inc.  Valencia,  CA)  and  then
suspended  with  Hi  Di  Formamide  (Applied  Biosystems,
Foster  city,CA)  to  run  on  the  3130xl  Genetic  Analyzer
(Applied Biosystems).
Statistical analysis: This is a case-control study in which the
frequency of HLA-DRB1 alleles in Saudi patients with VKH
disease  was  compared  with  the  frequency  of  HLA-DRB1
alleles in a similar group of Saudis without the VKH disease
(controls). The risk of the disease was estimated by the odds
ratio and calculation of the 95% confidence interval of the
odds  ratio.  A  p-value  of  less  than  0.05  was  considered
significant.
RESULTS
A total of 30 patients with VKH from the Eye Center and the
Eye  Foundation  for  Research  in  Ophthalmology  (Riyadh,
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There were 15 patients with complete VKH and 15 patients
with incomplete VKH. A total of 29 healthy volunteer subjects
were included. The healthy volunteers were not related to
patients with VKH or to each other and were of the same ethnic
origin.
Table 1 summarizes the gene frequencies of HLA-DRB1
alleles for VKH patients and the control group. No significant
differences were observed in HLA-DRB1 frequencies between
the patients with VKH and control group. However, when the
HLA-DRB1 *04 were subtyped, the HLA-DRB1 *0405 allele
was found to be positively associated with VKH in the Saudi
population (p=0.01). The frequency of HLA-DRB1 *0401 and
HLA- DRB1 *0410 were measured to be very low in the
normal Saudi population (unpublished). Accordingly, these
alleles  were  not  detected  in  our  study  population  (VKH
patients and matched controls). On the other hand, the HLA-
DRB1 *0301 and *0403 alleles were found to be higher in the
control group than what have been observed in the patients
with  VKH  despite  achieving  statistically  insignificant
association, indicating a possible protective role of these two
alleles against the disease (Table 1). To assess the significance
of the association of HLA-DRB1 *0405 alleles and the VKH
disease, the association of HLA-DRB1 *0405 with complete
VKH and incomplete VKH was analyzed. Five out of fifteen
cases  of  complete  VKH  and  6  out  of  15  patients  with
incomplete VKH had positive HLA-DRB1 *0405 with no
statistically  significant  difference  (data  not  shown).  The
frequency of HLA-DBR1 *0701 allele was found to be the
highest among all the alleles of HLA-DRB1 in both VKH
patients  and  controls.  On  the  other  hand,  no  statistically
significant differences were detected in the HLA-DRB1 alleles
*01, *0101, *0102, *0301, *04, *0403, *0404, *0701, *1001,
*1101, *1112, *1301, *1302, *1303, *1501, and *1502 (Table
1).
DISCUSSION
Association of the HLA-DRB1 *0405 allele and VKH disease
has  already  been  reported  in  the  other  races  [8,11,12].
However,  this  is  the  first  report  studying  the  genetic
predisposition of a very important autoimmune disease, Vogt-
Koyanagi-Harada  Disease  (VKH),  in  Saudi  Arabia.  We
performed complete HLA-DRB1 genotyping and found that
HLA-DRB1 *0405 was significantly associated with VKH
disease, and no such association was noted with HLA-DRB1
*0404. The association between class I antigen and VKH
disease  may  differ  among  various  ethnic  groups.  Among
Koreans, HLA-DRB1 *04 was positive in 17 (94.4%) out of
18 patients [11]. Although the clinical manifestations of VKH
are well outlined [7], the exact etiology of this condition
remains to be elucidated. It has been suggested the mechanism
could  be  a  T-lymphocyte-mediated  autoimmune  process
directed against an unidentified antigen or a group of antigens
associated  with  the  melanocytes  [1,4,5].  Although  the
mechanism  that  triggers  this  autoimmune  attack  against
melanocytes is unknown, sensitization to melanocytes has
been proposed [5]. While the exact target antigen has not been
identified, several candidates were proposed. This includes
tyrosinase or tyrosinase-related proteins and a 75 kDa protein
obtained  from  cultured  human  melanoma  cells  [13].  The
etiology of VKH syndrome is not certain, but the clinical
history of VKH syndrome mimics an influenza attack, which
implies a viral or post infectious origin. An Epstein-Barr virus
reactivation in this disease has been suggested [14]. Although
a viral cause has been projected, no virus has been isolated or
cultured  from  patients  with  VKH  syndrome.  Morris  and
Schlaegel  [15]  found  virus-like  inclusion  bodies  in  the
subretinal fluid of a patient with the VKH syndrome. An
association between HLA-DRB1 *0405 and VKH has been
noted among patients from Japan, Brazil, Korea, and Mexico
[8,9,11,12,16].  Therefore,  a  genetically  determined
susceptibility to the triggering event for the VKH disease has
been suggested [5,17]. The data presented here confirmed an
association of HLA-DRB1 *0405 with the VKH patients in
Saudi Arabia. This relationship was similar to those reported
from Japan and Brazil [8,12]. Out of the HLA-DRB1 *04
subtypes, HLA-DRB1 *0405 had the strongest association
with the VKH disease [11]. The association of HLA-DRB1
*0405  among  Brazilian  patients  with  VKH  may  reflect  a
genetic pool inherited from Japanese descendants. Kim and
associates found that HLA-DRB1 *0405 was greatly increased
in patients with VKH syndrome among Koreans and might
have an important role in the development of the clinical
course of VKH [11]. On the other hand, HLA-DRB1 alleles
such as *0705, *1001, *1101, *1112,*1301, *1302, *1303,
*1501,  and  *1502  showed  no  statistically  significant
differences  between  VKH  patients  and  controls.  Genetic
predisposition and environmental triggers may play a role in
the pathogenesis of VKH in Saudi Arabia. Alternatively, the
diagnostic criteria of the VKH disease were revised recently
in a cohort of VKH Brazilian patients wherein no association
was found between disease categories, the presence of HLA-
DRB1 *0405, and the clinical parameters [16]. We think that
differences  in  the  genetic  background  in  different
geographical areas might contribute to these discrepancies
and that more studies need to be done before the previous
statement can be generalized. In Korean patients with VKH
disease, HLA-DQA1 *0301 was less frequently detected than
in normal control subjects whereas the frequency of HLA-
DQA1 *0302 was increased [11]. These findings suggest that
gene association with VKH disease in the HLA region is
located between the HLA- DRB1 locus and the HLA-DQB1
locus. Shindo and others [8] have reported the presence of
HLA-DRB1  *0405  and/or  HLA-DRB1  *0410  in  the  VKH
patients. Moreover, they reported that the VKH patients who
did not have HLA-DRB1 *0405 possess HLA-DRB1 *0410
alleles, suggesting that the susceptibility to VKH disease was
determined by the presence of the shared functional epitope
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But, these alleles were not detected in our study population in
either  the  VKH  patients  or  their  matched  controls  as  the
frequency of HLA- DRB1 *0401 and HLA-DRB1 *0410 were
measured  to  be  very  low  in  the  normal  Saudi  population
(unpublished). To conclude, patients with VKH had a higher
incidence  of  HLA-DRB1  *0405,  indicating  that  the  HLA-
DRB1 *0405 allele might play a role in the pathogenesis of
VKH disease.
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